Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Polyneuropathy that is characterized by demyelination of axons.
Biomarker and diagnostic research for demyelinating polyneuropathy has been reported in the published literature.
37 clinical trials registered, 21 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and medical devices. Pipeline includes 3 PHASE4, 7 PHASE3, 7 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07154524](https://clinicaltrials.gov/study/NCT07154524) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:22 AM UTC
Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
— |
University of Ulm |
RECRUITING |
[NCT07461896](https://clinicaltrials.gov/study/NCT07461896) | Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP | — | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
[NCT07032662](https://clinicaltrials.gov/study/NCT07032662) | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | PHASE2 | Immunovant Sciences GmbH | RECRUITING |
[NCT04589299](https://clinicaltrials.gov/study/NCT04589299) | Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) | PHASE4 | University of Aarhus | RECRUITING |
[NCT07091630](https://clinicaltrials.gov/study/NCT07091630) | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | PHASE3 | argenx | RECRUITING |
303 publications have been identified in PubMed for demyelinating polyneuropathy. Research spans Case Report / Case Series (25%), Review / Meta-Analysis (24%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 75 | 25% |
Research summaries | 72 | 24% |
Laboratory research | 39 | 13% |
Disease patterns and progression | 38 | 13% |
Testing and diagnosis research | 35 | 12% |
Clinical study results | 33 | 11% |
New treatment approaches | 8 | 3% |
Other research | 3 | 1% |
Liu L (2026). [PMID: 42207162](https://pubmed.ncbi.nlm.nih.gov/42207162/). *Immun Inflamm Dis*. [Case Report / Case Series]
Jaiswal S (2026). [PMID: 41429674](https://pubmed.ncbi.nlm.nih.gov/41429674/). *International ophthalmology clinics*. [Diagnostic / Biomarker]
Elmas Z (2026). [PMID: 41567712](https://pubmed.ncbi.nlm.nih.gov/41567712/). *EClinicalMedicine*. [Clinical Trial Publication]
Mendez R (2026). [PMID: 41808409](https://pubmed.ncbi.nlm.nih.gov/41808409/). *HGG Adv*. [Case Report / Case Series]
Amro OW (2026). [PMID: 42078607](https://pubmed.ncbi.nlm.nih.gov/42078607/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Yang M (2026). [PMID: 42090080](https://pubmed.ncbi.nlm.nih.gov/42090080/). *Neurol Ther*. [Clinical Trial Publication]
Karam C (2026). [PMID: 41263294](https://pubmed.ncbi.nlm.nih.gov/41263294/). *Muscle & nerve*. [Diagnostic / Biomarker]
Wang Y (2026). [PMID: 41876953](https://pubmed.ncbi.nlm.nih.gov/41876953/). *Ann Neurol*. [Basic Science / Preclinical]
File C (2026). [PMID: 42051912](https://pubmed.ncbi.nlm.nih.gov/42051912/). *Front Dement*. [Case Report / Case Series]
Wang X (2026). [PMID: 41695471](https://pubmed.ncbi.nlm.nih.gov/41695471/). *Theranostics*. [Gene Therapy / Novel Therapeutics]